Paul Audhya

3.9k total citations · 3 hit papers
46 papers, 2.9k citations indexed

About

Paul Audhya is a scholar working on Nephrology, Genetics and Hematology. According to data from OpenAlex, Paul Audhya has authored 46 papers receiving a total of 2.9k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Nephrology, 16 papers in Genetics and 16 papers in Hematology. Recurrent topics in Paul Audhya's work include Dialysis and Renal Disease Management (16 papers), Erythropoietin and Anemia Treatment (12 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers). Paul Audhya is often cited by papers focused on Dialysis and Renal Disease Management (16 papers), Erythropoietin and Anemia Treatment (12 papers) and Coagulation, Bradykinin, Polyphosphates, and Angioedema (9 papers). Paul Audhya collaborates with scholars based in United States, Germany and United Kingdom. Paul Audhya's co-authors include Colin J. Meyer, Melissa Krauth, Robert D. Toto, Heidi Christ‐Schmidt, Janet Wittes, Dick de Zeeuw, Giuseppe Remuzzi, Dennis L. Andress, Yili Pritchett and Τushar Garimella and has published in prestigious journals such as New England Journal of Medicine, The Lancet and American Journal of Epidemiology.

In The Last Decade

Paul Audhya

41 papers receiving 2.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease

2013 784 citations Dick de Zeeuw, Paul Audhya et al. New England Journal of Medicine profile →
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

2011 707 citations Pablo E. Pérgola, Philip Raskin et al. New England Journal of Medicine profile →
Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

2010 520 citations Dick de Zeeuw, Rajiv Agarwal et al. The Lancet profile →

Peers

Countries citing papers authored by Paul Audhya

Since Specialization

Citations

This map shows the geographic impact of Paul Audhya's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Paul Audhya with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Paul Audhya more than expected).

Fields of papers citing papers by Paul Audhya

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Paul Audhya. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Paul Audhya. The network helps show where Paul Audhya may publish in the future.

Co-authorship network of co-authors of Paul Audhya

This figure shows the co-authorship network connecting the top 25 collaborators of Paul Audhya. A scholar is included among the top collaborators of Paul Audhya based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Paul Audhya. Paul Audhya is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SEBETRALSTAT FOR ON-DEMAND TREATMENT OF HEREDITARY ANGIOEDEMA IN PEDIATRIC (2-11Y) PATIENTS: INTERIM RESULTS FROM KONFIDENT-KID 2025 ·Annals of Allergy Asthma & Immunology ·Adil Adatia, Emel Aygören‐Pürsün, Mauro Cancian, Aaron Kessel, (unknown), (unknown), H. James Wedner, (unknown), Yu‐Chung Chuang, (unknown), Michael F. Smith, Paul Audhya, (unknown)	0
2	Study to Adjudicate Hereditary Angioedema with Normal C1INH Diagnoses in the PIONEER-HAE Database 2025 ·Journal of Allergy and Clinical Immunology ·Maeve O’Connor, (unknown), Scott Milligan, (unknown), Paul Audhya, Marc A. Riedl	0
3	Advent of oral medications for the treatment of hereditary angioedema 2024 ·Clinical and Translational Allergy ·Anna Valerieva, Teresa Caballero, (unknown), (unknown), Paul Audhya, Timothy Craig	1
4	Hereditary Angioedema Attacks in Patients Receiving Long-Term Prophylaxis: A Systematic Review 2024 ·Clinical Reviews in Allergy & Immunology ·Hilary Longhurst, Mauro Cancian, Vesna Grivcheva‐Panovska, (unknown), (unknown), Sinisa Savic, Marcin Stobiecki, Raffi Tachdjian, Bridget Healy, Christopher Yea, Paul Audhya, Laurence Bouillet	5
5	On-demand treatment of hereditary angioedema attacks 2024 ·Annals of Allergy Asthma & Immunology ·Sandra C. Christiansen, Maeve O’Connor, (unknown), Cristine Radojicic, H. James Wedner, Sherry Danese, (unknown), (unknown), (unknown), (unknown), Paul Audhya, Paula J. Busse	1
6	Tezacaftor/ivacaftor in people with cystic fibrosis who stopped lumacaftor/ivacaftor due to respiratory adverse events 2020 ·Journal of Cystic Fibrosis ·C. Schwarz, Sivagurunathan Sutharsan, Ralph Epaud, Ross C. Klingsberg, Rainald Fischer, Steven M. Rowe, Paul Audhya, Neil Ahluwalia, Xiaojun You, Thomas J. Ferro, Margaret E. Duncan, Bote G. Bruinsma	18
7	P484. Access to biologics and biosimilars across 11 European Union countries 2016 ·Journal of Crohn s and Colitis ·Samuel Fernandes, Cilénia Baldaia, Paulo Moura, Andrey Santos, Ana Rita Gonçalves, (unknown), (unknown), Péter L. Lakatos, Eugeni Domènech, H. Kellner, Jan Marsal, Henry W. Fowler, (unknown), (unknown), (unknown), Saeed Anwar, (unknown), Paul Audhya, (unknown)	1
8	Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes breakdown → 2011 ·New England Journal of Medicine ·Pablo E. Pérgola, Philip Raskin, Robert D. Toto, Colin J. Meyer, Jesse W. Huff, Eric Grossman, Melissa Krauth, Stacey Ruiz, Paul Audhya, Heidi Christ‐Schmidt, Janet Wittes, David G. Warnock	707
9	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial breakdown → 2010 ·The Lancet ·Dick de Zeeuw, Rajiv Agarwal, Michael Amdahl, Paul Audhya, Daniel W. Coyne, Τushar Garimella, Hans‐Henrik Parving, Yili Pritchett, Giuseppe Remuzzi, Eberhard Ritz, Dennis L. Andress	520
10	Physical and Psychological Burden of Chronic Kidney Disease among Older Adults 2010 ·American Journal of Nephrology ·William M. McClellan, Jerome L. Abramson, Britt B. Newsome, (unknown), Virginia G. Wadley, Paul Audhya, Leslie A. McClure, Virginia J. Howard, David G. Warnock, Paul L. Kimmel	49
11	Comparative Effectiveness of Paricalcitol versus Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis 2010 ·Nephron Clinical Practice ·Glen T. Schumock, Surrey M. Walton, Todd A. Lee, Steven E. Marx, Paul Audhya, Dennis L. Andress	7
12	The Selective Vitamin D Receptor Activator for Albuminuria Lowering (VITAL) Study: Study Design and Baseline Characteristics 2009 ·American Journal of Nephrology ·Hiddo J.L. Heerspink, Rajiv Agarwal, Daniel W. Coyne, H.‐H. Parving, Eberhard Ritz, Giuseppe Remuzzi, Paul Audhya, Michael Amdahl, D.L. Andress, Dick de Zeeuw	28
13	A US multicenter, retrospective, observational study of erythropoiesis-stimulating agent utilization in anemic, critically ill patients admitted to the intensive care unit 2008 ·Clinical Therapeutics ·Gretchen M. Brophy, (unknown), Marc J. Shapiro, Lawrence Lottenberg, Debra Scarlata, Paul Audhya	6
14	Chronic Kidney Disease Is Often Unrecognized among Patients with Coronary Heart Disease: The REGARDS Cohort Study 2008 ·American Journal of Nephrology ·William M. McClellan, Britt B. Newsome, Leslie A. McClure, Mary Cushman, George Howard, Paul Audhya, Jerome L. Abramson, David G. Warnock	27
15	Correlates of Anemia in American Blacks and Whites: The REGARDS Renal Ancillary Study 2008 ·American Journal of Epidemiology ·Neil A. Zakai, Leslie A. McClure, Ronald J. Prineas, George Howard, William McClellan, Chris E. Holmes, Britt B. Newsome, David G. Warnock, Paul Audhya, Mary Cushman	65
16	Prevalence and Characteristics of a Family History of End-Stage Renal Disease among Adults in the United States Population 2007 ·Journal of the American Society of Nephrology ·William McClellan, Rebecca A. Speckman, Leslie A. McClure, Virginia J. Howard, Ruth Campbell, Mary Cushman, Paul Audhya, George Howard, David G. Warnock	34
17	Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis 2006 ·Current Medical Research and Opinion ·Jeffrey Hoggard, (unknown), Stephen E. McMurray, (unknown), (unknown), Debra Scarlata, Paul Audhya	12
18	Once-Monthly Darbepoetin alfa for Maintaining Hemoglobin Levels in Older Patients With Chronic Kidney Disease 2006 ·Journal of the American Medical Directors Association ·Avinash Kumar Ágarwal, (unknown), (unknown), Weixin Liu, Paul Audhya	11
19	Darbepoetin alfa Administered Every Other Week Maintains Hemoglobin Levels over 52 Weeks in Patients with Chronic Kidney Disease Converting from Once-Weekly Recombinant Human Erythropoietin: Results from Simplify the Treatment of Anemia with Aranesp (STAAR) 2006 ·American Journal of Nephrology ·Joachim Hertel, (unknown), Debra Scarlata, (unknown), (unknown), Paul Audhya	30
20	Prevalence of chronic kidney disease and anemia among participants in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Cohort Study: Baseline results 2005 ·Kidney International ·David G. Warnock, William McClellan, Leslie A. McClure, Britt B. Newsome, Ruth Campbell, Paul Audhya, Mary Cushman, Virginia J. Howard, George Howard	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact